Condition: Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL) · Sponsor: Dana-Farber Cancer Institute
This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
This description comes directly from the study's public registry record.
DFCI Clinical Trials Hotline · 877-DF-TRIAL · DFCILymphomaResearchNurses@partners.org
Always discuss trial participation with your own doctor first.
| New England Cancer Specialists | Scarborough, Maine, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| South Shore Hospital | South Weymouth, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05168930